Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Atopic | 12 | 2020 | 103 | 4.100 |
Why?
|
| Dermatologic Agents | 7 | 2020 | 233 | 2.300 |
Why?
|
| Skin Neoplasms | 4 | 2019 | 220 | 1.620 |
Why?
|
| Myoclonic Epilepsies, Progressive | 2 | 2018 | 2 | 1.130 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 2 | 2018 | 5 | 1.130 |
Why?
|
| Epidermis | 2 | 2018 | 29 | 1.120 |
Why?
|
| Dermatology | 3 | 2019 | 157 | 1.070 |
Why?
|
| Psoriasis | 3 | 2020 | 355 | 1.050 |
Why?
|
| Scabies | 2 | 2017 | 2 | 1.030 |
Why?
|
| Humans | 47 | 2020 | 32286 | 1.030 |
Why?
|
| Syphilis, Congenital | 2 | 2017 | 3 | 0.900 |
Why?
|
| Biological Products | 5 | 2020 | 79 | 0.890 |
Why?
|
| Boron Compounds | 3 | 2020 | 11 | 0.870 |
Why?
|
| Skin | 4 | 2020 | 213 | 0.810 |
Why?
|
| Eczema | 3 | 2019 | 14 | 0.750 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 245 | 0.740 |
Why?
|
| Drugs, Investigational | 2 | 2020 | 9 | 0.730 |
Why?
|
| Lafora Disease | 2 | 2018 | 2 | 0.710 |
Why?
|
| Skin Diseases | 2 | 2019 | 135 | 0.650 |
Why?
|
| Drug Eruptions | 1 | 2020 | 9 | 0.640 |
Why?
|
| Antiparasitic Agents | 2 | 2017 | 6 | 0.640 |
Why?
|
| Students, Health Occupations | 1 | 2020 | 7 | 0.620 |
Why?
|
| Herpes Zoster | 1 | 2019 | 12 | 0.610 |
Why?
|
| Problem-Based Learning | 1 | 2020 | 29 | 0.610 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 42 | 0.610 |
Why?
|
| Leukemia | 1 | 2019 | 38 | 0.600 |
Why?
|
| Neck | 1 | 2019 | 32 | 0.600 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2019 | 27 | 0.590 |
Why?
|
| Heart Transplantation | 1 | 2019 | 33 | 0.590 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 39 | 0.580 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 59 | 0.580 |
Why?
|
| Eosinophilia | 1 | 2019 | 11 | 0.580 |
Why?
|
| Erythrocytes | 1 | 2018 | 41 | 0.560 |
Why?
|
| Pruritus | 2 | 2020 | 46 | 0.550 |
Why?
|
| Child | 9 | 2020 | 2432 | 0.540 |
Why?
|
| Melanoma | 1 | 2019 | 166 | 0.530 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 3 | 0.530 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 156 | 0.530 |
Why?
|
| Adult | 13 | 2020 | 9263 | 0.520 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 40 | 0.520 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2017 | 17 | 0.520 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2016 | 5 | 0.500 |
Why?
|
| Female | 17 | 2020 | 19955 | 0.480 |
Why?
|
| Adolescent | 7 | 2020 | 3519 | 0.460 |
Why?
|
| Referral and Consultation | 1 | 2016 | 138 | 0.460 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 501 | 0.450 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2015 | 9 | 0.440 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2015 | 12 | 0.440 |
Why?
|
| Male | 15 | 2020 | 19448 | 0.440 |
Why?
|
| Infant | 4 | 2019 | 1010 | 0.430 |
Why?
|
| Administration, Cutaneous | 4 | 2019 | 116 | 0.410 |
Why?
|
| Dermatomyositis | 2 | 2016 | 18 | 0.390 |
Why?
|
| Administration, Oral | 3 | 2018 | 200 | 0.380 |
Why?
|
| Blister | 1 | 2012 | 7 | 0.380 |
Why?
|
| Extremities | 1 | 2012 | 51 | 0.370 |
Why?
|
| Livedo Reticularis | 1 | 2012 | 2 | 0.370 |
Why?
|
| Indans | 1 | 2012 | 31 | 0.360 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3612 | 0.350 |
Why?
|
| Leg | 1 | 2012 | 67 | 0.350 |
Why?
|
| Biopsy, Needle | 4 | 2019 | 93 | 0.350 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 854 | 0.320 |
Why?
|
| Middle Aged | 10 | 2019 | 11848 | 0.320 |
Why?
|
| Pemphigus | 1 | 2010 | 8 | 0.320 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 544 | 0.320 |
Why?
|
| Diet | 2 | 2013 | 383 | 0.310 |
Why?
|
| Prognosis | 4 | 2018 | 1529 | 0.300 |
Why?
|
| Infant, Newborn | 3 | 2017 | 666 | 0.300 |
Why?
|
| Algorithms | 1 | 2012 | 536 | 0.290 |
Why?
|
| Drug Utilization | 1 | 2008 | 44 | 0.280 |
Why?
|
| Aged | 7 | 2020 | 10259 | 0.280 |
Why?
|
| Food, Formulated | 1 | 2008 | 13 | 0.270 |
Why?
|
| Deglutition Disorders | 1 | 2008 | 52 | 0.260 |
Why?
|
| Antipruritics | 2 | 2018 | 4 | 0.260 |
Why?
|
| Permethrin | 2 | 2017 | 2 | 0.260 |
Why?
|
| Ivermectin | 2 | 2017 | 9 | 0.260 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 3899 | 0.250 |
Why?
|
| Risk Assessment | 4 | 2019 | 1424 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 325 | 0.230 |
Why?
|
| Calcitriol | 2 | 2020 | 29 | 0.230 |
Why?
|
| Child, Preschool | 2 | 2019 | 1234 | 0.210 |
Why?
|
| Young Adult | 4 | 2019 | 2652 | 0.210 |
Why?
|
| Hospitalization | 2 | 2018 | 475 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 115 | 0.200 |
Why?
|
| Quality of Life | 3 | 2019 | 970 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3409 | 0.180 |
Why?
|
| Double-Blind Method | 2 | 2020 | 567 | 0.170 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 4 | 0.160 |
Why?
|
| Aerosols | 1 | 2020 | 15 | 0.160 |
Why?
|
| Biological Therapy | 1 | 2020 | 18 | 0.160 |
Why?
|
| Serum Sickness | 1 | 2020 | 1 | 0.160 |
Why?
|
| Scalp | 1 | 2020 | 35 | 0.160 |
Why?
|
| Pseudolymphoma | 1 | 2020 | 5 | 0.160 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2020 | 13 | 0.160 |
Why?
|
| Granuloma | 1 | 2020 | 14 | 0.160 |
Why?
|
| Exanthema | 1 | 2020 | 19 | 0.160 |
Why?
|
| Azetidines | 1 | 2020 | 11 | 0.160 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2020 | 9 | 0.160 |
Why?
|
| Students, Nursing | 1 | 2020 | 6 | 0.160 |
Why?
|
| Herpesvirus 3, Human | 1 | 2019 | 5 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 293 | 0.150 |
Why?
|
| Sweet Syndrome | 1 | 2019 | 6 | 0.150 |
Why?
|
| Nail Diseases | 1 | 2019 | 5 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2020 | 86 | 0.150 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2019 | 5 | 0.150 |
Why?
|
| Cellulitis | 1 | 2019 | 12 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 10 | 0.150 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 23 | 0.150 |
Why?
|
| Keratosis | 1 | 2019 | 22 | 0.150 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 24 | 0.150 |
Why?
|
| Dermoscopy | 1 | 2019 | 12 | 0.150 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 74 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2019 | 107 | 0.150 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2019 | 3 | 0.150 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 157 | 0.150 |
Why?
|
| Calciphylaxis | 1 | 2018 | 1 | 0.140 |
Why?
|
| Pediatrics | 1 | 2020 | 156 | 0.140 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 47 | 0.140 |
Why?
|
| Public Opinion | 1 | 2018 | 17 | 0.140 |
Why?
|
| Acute Disease | 1 | 2019 | 253 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 106 | 0.140 |
Why?
|
| Drug Design | 1 | 2018 | 51 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2019 | 53 | 0.140 |
Why?
|
| Sex Factors | 2 | 2018 | 656 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 138 | 0.140 |
Why?
|
| Pemphigoid Gestationis | 1 | 2018 | 3 | 0.140 |
Why?
|
| Curriculum | 1 | 2020 | 203 | 0.140 |
Why?
|
| Students, Medical | 1 | 2020 | 126 | 0.140 |
Why?
|
| Drug Approval | 1 | 2017 | 13 | 0.130 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2018 | 26 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 411 | 0.130 |
Why?
|
| Penicillins | 1 | 2017 | 12 | 0.130 |
Why?
|
| Treponema pallidum | 1 | 2017 | 7 | 0.130 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 8 | 0.130 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 52 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2018 | 148 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 90 | 0.130 |
Why?
|
| Foot | 1 | 2017 | 40 | 0.130 |
Why?
|
| Developing Countries | 1 | 2017 | 57 | 0.130 |
Why?
|
| Age Factors | 2 | 2018 | 1178 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2019 | 394 | 0.130 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2017 | 10 | 0.120 |
Why?
|
| Microscopy | 1 | 2017 | 28 | 0.120 |
Why?
|
| Southeastern United States | 1 | 2017 | 75 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2016 | 85 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 38 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2017 | 38 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2017 | 164 | 0.120 |
Why?
|
| Disease Progression | 1 | 2018 | 591 | 0.120 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2016 | 2 | 0.120 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2016 | 6 | 0.120 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 6 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2017 | 111 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 312 | 0.120 |
Why?
|
| Animals | 2 | 2018 | 8197 | 0.120 |
Why?
|
| Mycophenolic Acid | 2 | 2017 | 42 | 0.110 |
Why?
|
| Prevalence | 1 | 2017 | 955 | 0.110 |
Why?
|
| Panniculitis, Lupus Erythematosus | 1 | 2014 | 6 | 0.110 |
Why?
|
| Psychometrics | 1 | 2015 | 137 | 0.100 |
Why?
|
| Scurvy | 1 | 2013 | 3 | 0.100 |
Why?
|
| Methotrexate | 2 | 2017 | 70 | 0.100 |
Why?
|
| Incidence | 1 | 2017 | 1243 | 0.100 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.100 |
Why?
|
| United States | 2 | 2020 | 4077 | 0.100 |
Why?
|
| Immunosuppression | 1 | 2012 | 118 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2012 | 136 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2012 | 87 | 0.080 |
Why?
|
| Remission Induction | 1 | 2010 | 92 | 0.080 |
Why?
|
| Prednisone | 1 | 2010 | 69 | 0.080 |
Why?
|
| Pemphigoid, Bullous | 2 | 2019 | 9 | 0.080 |
Why?
|
| Fever | 2 | 2019 | 60 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 2008 | 18 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 550 | 0.070 |
Why?
|
| Barium | 1 | 2008 | 4 | 0.070 |
Why?
|
| Viscosity | 1 | 2008 | 25 | 0.070 |
Why?
|
| Rheology | 1 | 2008 | 35 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 545 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 249 | 0.060 |
Why?
|
| Age of Onset | 1 | 2020 | 91 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 48 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 104 | 0.040 |
Why?
|
| Streptococcus | 1 | 2019 | 8 | 0.040 |
Why?
|
| Thigh | 1 | 2019 | 35 | 0.040 |
Why?
|
| Fingers | 1 | 2019 | 75 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 36 | 0.040 |
Why?
|
| Perception | 1 | 2018 | 99 | 0.030 |
Why?
|
| Chikungunya virus | 1 | 2017 | 1 | 0.030 |
Why?
|
| Pain | 1 | 2020 | 303 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2018 | 122 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 180 | 0.030 |
Why?
|
| Hypopigmentation | 1 | 2017 | 7 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 160 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 174 | 0.030 |
Why?
|
| Skin Pigmentation | 1 | 2017 | 27 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2017 | 68 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2018 | 275 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2017 | 146 | 0.030 |
Why?
|
| Neurofibromatosis 2 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neurofibromatosis 1 | 1 | 2016 | 11 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2017 | 99 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 444 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 961 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2238 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 534 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 142 | 0.020 |
Why?
|